Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, is going to launch its initial public offering on 27 July 2021. The initial public offering (IPO) comprises a fresh issue of Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares by promoter Glenmark Pharmaceuticals.
The manufacturer of Active Pharmaceutical Ingredients (APIs) has about 120 APIs in its portfolio, which are supplied to more than 540 pharma companies across the world.
At present, about 50% of it sales are coming from North America, Europe, Latin America and Japan. China is one of its main destinations in sourcing raw materials such as chemicals and intermediates. However, the company said it is actively developing other suppliers.
The company has an aggregate annual total installed capacity of 726.6 kl at the end of fiscal year 2021. It currently operates four multi-purpose manufacturing facilities at Ankleshwar (511 kl) and Dahej (141.9 kl) in Gujarat, and Mohol (49.1 kl) and Kurkumbh (24.6 kl) in Maharashtra.
The company plans to utilise the net Proceeds towards the following purposes:
Company's Profit And Loss Summary
The pharmaceutical company’s revenue from operation increased 22.62% to Rs 1885.17 crore in FY21. In FY20, operating revenue rose 73.43% to Rs 1537.31 crore. Profit after tax rose 12.29% to Rs 351.58 crore in FY21. It rose 60.07% to Rs 313.09 crore in FY20. Its earnings per share rose 12.3% and 17.85% in FY21 and FY20, respectively. Below is the profit and loss statement of the company for the last three financial years.
Overview Of Global API Market
The API market around the world is expected to grow at a compounded annual growth rate (CAGR) of 6.2% to $259.3 billion by 2026, from its current size of $181.3 billion. The bulk drug industry in India is also likely to grow at 9.6% between fiscal year 2021 and 2026, after the industry saw a CAGR growth of 9% from 2016 to 2020. This growth potential offers a lot of opportunities for the company in a changing environment of the pharmaceutical industry, with price and regulatory enforcement being two of the most significant drivers of change.
Glenmark Pharmaceuticals Limited is the promoter of the company.
IPO Details
IPO Opening Date | July 27, 2021 |
IPO Closing Date | July 29, 2021 |
Issue Type | Book Built Issue IPO |
Face Value | Rs 2 per equity share |
IPO Price | Rs 695 to Rs 720 per equity share |
Market Lot | 20 Shares |
Min Order Quantity | 20 Shares |
Listing Exchanges | NSE,BSE |
Expected Date of Listing | August 6, 2021 |
IPO Lot Size
Glenmark Life Sciences’ IPO market lot size is 20 shares. A retail investor can apply up to 13 lots (260 shares or ₹187,200).
Application | Lots | Shares | Amount (Cut-off) |
Minimum | 1 | 20 | Rs 14,400 |
Maximum | 13 | 260 | Rs 187,200 |
Fortune Capital Services Private Ltd. SEBI Registration No. INZ000201438. Member Code for NSE: 14572 BSE:6524 MCX: 16765 and ICEX: 2010. CDSL DP ID: 12080300 SEBI Registration No.IN-DP-CDSL-729-2014. Registered Office: Kochar Technology Park, 6th Floor, SP-31-A, 1st Cross Road, Ambattur Industrial Estate, Ambattur, Chennai – 600 058. For any complaints pertaining to stock broking please write to [email protected] and for DP related to [email protected] Please ensure to read the Risk Disclosure Document carefully as prescribed by SEBI.
“Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances”
“Prevent unauthorised transactions in your account, update your mobile numbers/email IDs with your Stockbroker/Depository Participant. Receive information of your transactions directly from Exchange/Depository on your mobile/ email at the end of the day. Issued in the interest of investors”. As a business we do not give stock tips and have not authorized anyone to trade on behalf of others. If you find anyone claiming to be part of FLATTRADE and offering such services, please email to [email protected] “KYC is one time exercise while dealing in securities markets – once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.” Dear Investor, if you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non-allotment, the funds will remain in your bank account.
“Attention Investors 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. 2.Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 3. Pay 20% upfront margin of the transaction value to trade in cash market segment 4. Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. Issued in the interest of Investors”
Disclaimer: ‘Investment in securities market are subject to market risks, read all the related documents carefully before investing’.
“Investment in Mutual Fund market are subject to market risk. There is no guaranteed or assured rate of return. Past Performance is not indication of future returns. Please read all related documents carefully before investing”.
“The securities quoted are exemplary and are not recommendatory”.
“Brokerage will not exceed the SEBI prescribed limit”.
Leave a Reply